about
Depressive spectrum disorders in cancer: prevalence, risk factors and screening for depression: a critical review.Affective syndromes and their screening in cancer patients with early and stable disease: Italian ICD-10 data and performance of the Distress Thermometer from the Southern European Psycho-Oncology Study (SEPOS)."Caseness" for depression and anxiety in a depressed outpatient population: symptomatic outcome as a function of baseline diagnostic categories.Depressive Spectrum Disorders in Cancer: Diagnostic Issues and Intervention. A Critical Review.2015 President's Plenary International Psycho-oncology Society: psychosocial care as a human rights issue-challenges and opportunities.Schizophrenia and quality of life: how important are symptoms and functioning?The MentDis_ICF65+ study protocol: prevalence, 1-year incidence and symptom severity of mental disorders in the elderly and their relationship to impairment, functioning (ICF) and service utilisation.Exploration of experiences in therapeutic groups for patients with severe mental illness: development of the Ferrara group experiences scale (FE- GES).Integrating psychosocial care into neuro-oncology: challenges and strategies.Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review.Sales of antidepressants, suicides and hospital admissions for depression in Veneto Region, Italy, from 2000 to 2005: an ecological studyDepression in HIV infected patients: a review.Management of delirium in palliative care: a review.Disparities in psychosocial cancer care: A report from the International Federation of Psycho-Oncology Societies.2016 President's Plenary International Psycho-Oncology Society: challenges and opportunities for growing and developing psychosocial oncology programmes worldwide.5-HTTLPR polymorphism and anxious preoccupation in early breast cancer patients.Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia.Factors Influencing Depression Endpoints Research (FINDER): baseline results of Italian patients with depression.Burnout among psychosocial oncologists: an application and extension of the effort-reward imbalance model.An exploration of the prevalence and predictors of work-related well-being among psychosocial oncology professionals: An application of the job demands-resources model.Somatization and somatic symptom presentation in cancer: a neglected area.Psychopharmacology in psycho-oncology.Validation of the distress thermometer worldwide: state of the science.Communication with patients suffering from serious physical illness.The expanding role of primary care in cancer control.Prevalence and correlates of somatoform disorders in the elderly: Results of a European study.2013 President's Plenary International Psycho-oncology Society: embracing the IPOS standards as a means of enhancing comprehensive cancer care.Prevalence of mental disorders in elderly people: the European MentDis_ICF65+ study.Awareness of cancer, satisfaction with care, emotional distress, and adjustment to illness: an Italian multicenter study.The Factors Influencing Depression Endpoints Research (FINDER) study: final results of Italian patients with depression.Depression and serotonin transporter (5-HTTLPR) polymorphism in breast cancer patients.Depression or hypoactive delirium? A report of ciprofloxacin-induced mental disorder in a patient with chronic obstructive pulmonary disease.Psychosomatic characterization of adjustment disorders in the medical setting: some suggestions for DSM-V.Suspected neuroleptic catatonia induced by clozapine.Factors related to admission of psychiatric patients to medical wards from the general hospital emergency department: a 3-year study of urgent psychiatric consultations.Do spirituality and faith make a difference? Report from the Southern European Psycho-Oncology Study Group.Emotional stress, psychosocial variables and coping associated with hepatitis C virus and human immunodeficiency virus infections in intravenous drug users.Irritable mood in Italian patients with medical disease.Communicating anticancer treatment cessation and transition to palliative care: The need for a comprehensive and culturally relevant, person-centered approach.Quetiapine may induce mania: a case report.
P50
Q30238703-E72F0696-931D-4330-A028-D838EDFE4486Q33364804-D21957C2-7EA1-4B93-857C-ECA0C752F620Q33587004-9F2309B2-1C94-4F84-98D0-0737283802A6Q33653724-633D9DF1-7208-457A-97D8-911663DB8F06Q33863803-476A844A-FB84-49F1-8477-6C3605AD58D6Q34468429-0AF32949-C7DE-4BEF-B0F9-4D74FEB17768Q34590551-69C77F9A-7B71-46BA-AFE0-A1F6A361841AQ35003768-EEECCCF6-DCB2-4E55-A93A-E307D392C003Q35110441-2FBF65C6-5A57-4320-939C-E520B60CA96AQ35143365-CD4104FD-F228-4829-A6BC-08AF8743346BQ35398237-B9A77993-7309-41D5-9F1C-C4ADAD5F8DF9Q35440924-FCD9D969-29FB-4064-AE4B-A6C7097F1479Q35557971-C3C40548-3D9E-423E-B5FE-2E3DEF56B360Q36084165-32F98D76-35B5-4ADF-B04D-60FE10D3EBB5Q36397075-E0EFB707-394D-46C5-B152-62439DAD235CQ36611281-1C8F9E40-7563-4A58-A77E-C28D89FAF443Q37209442-FC381CDF-773E-4216-95E9-7E4008609FE4Q37240212-6CEFF9D5-C8C5-45F0-90CC-CCB80810AE0EQ37537992-96D7AB22-64BA-4C75-9911-048E8D0E0CE1Q37603958-04DD0F34-2928-4E03-8C0B-D1E37ED2D1D1Q38079258-1DBD0BB6-2003-4ABC-881A-9FD36287F010Q38129301-C518646B-8F61-4BD5-97F8-DB38FA09B95DQ38243720-F927437D-33D5-45D6-B7C6-B3BBBE6F5BBEQ38400182-5C052DEE-133A-4520-B33B-250B0E513F53Q38598014-C81DCE8C-8C9C-4C95-B61F-8E374B8E4EFBQ38984990-CFC464D9-937F-4719-993D-9BA85723A401Q39171974-2CDAA0C3-6CB4-4DB8-B274-B7C540170BA4Q40588931-C2B25988-8D90-4424-A32A-4CEE94DE5DA0Q41365467-024DB478-89B2-4D0D-B297-FE456D0F4F72Q42532582-AFF55F71-CDAF-4425-85D8-0C78ADE15549Q43178198-055D4424-15EB-4A44-AA74-C32BD9D8D5A7Q43517673-841ABF6F-F6CB-454B-971C-6E4067DD0ABDQ43649060-3EDA8C3C-3ADD-4069-A62A-75CEBB805537Q43665210-5D8A7671-B44D-467E-BBCB-510A9D3F4062Q43686590-4419DAE2-EC75-4DAF-AAEE-8B02D53370A1Q43782529-7DF0CB60-8CD8-43D2-B85F-93DC8DF36F11Q43971317-9F3454C0-CF0B-4A1D-B723-1ECCBD1CE7B2Q44033312-A49ECB6F-E5D0-4FE6-9DFC-7B3455F256EAQ44382441-7A03A58B-4475-45AB-8FE8-A12183ADA997Q44515379-0B74EEC3-D804-4338-8C47-A10DA6A1B3B4
P50
description
researcher ORCID: 0000-0002-1050-4494
@en
name
Luigi Grassi
@ast
Luigi Grassi
@en
Luigi Grassi
@es
Luigi Grassi
@nl
type
label
Luigi Grassi
@ast
Luigi Grassi
@en
Luigi Grassi
@es
Luigi Grassi
@nl
prefLabel
Luigi Grassi
@ast
Luigi Grassi
@en
Luigi Grassi
@es
Luigi Grassi
@nl
P106
P1153
7005904642
P21
P31
P496
0000-0002-1050-4494